CoChat

Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

Open access
Reda, Moataz, Ngamcherdtrakul, Worapol, Nelson, Molly A., Siriwon, Natnaree, Wang, Ruijie, Zaidan, Husam Y., Bejan, Daniel S., Reda, Sherif, Hoang, Ngoc Ha, Crumrine, Noah A., Rehwaldt, Justin P. C., Bindal, Akash, Mills, Gordon B., Gray, Joe W., Yantasee, Wassana · 2022 · Nature Communications
Cited by 198

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients respond to ICIs, highlighting the need for superior immunotherapy. Herein, we report on a nanoparticle-based immunotherapy termed ARAC (Antigen Release Agent and Checkpoint Inhibitor) designed to enhance the efficacy of PD-L1 inhibitor. ARAC is a nanoparticle co-delivering PLK1 inhibitor (volasertib) and PD-L1 antibody. PLK1 is a key mitotic kinase that is overexpressed in various cancers including NSCLC and drives cancer growth. Inhibition of PLK1 selectively kills cancer cells and upregulates PD-L1 expression in surviving cancer cells thereby providing opportunity for ARAC targeted delivery in a feedforward manner. ARAC reduces effective doses of volasertib and PD-L1 antibody by 5-fold in a metastatic lung tumor model (LLC-JSP) and the effect is mainly mediated by CD8+ T cells. ARAC also shows efficacy in another lung tumor model (KLN-205), which does not respond to CTLA-4 and PD-1 inhibitor combination. This study highlights a rational combination strategy to augment existing therapies by utilizing our nanoparticle platform that can load multiple cargo types at once.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-31926-9

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Metadata

Authors
Reda, M., Ngamcherdtrakul, W., Nelson, M. A., Siriwon, N., Wang, R., Zaidan, H. Y., Bejan, D. S., Reda, S., Hoang, N. H., Crumrine, N. A., Rehwaldt, J. P. C., Bindal, A., Mills, G. B., Gray, J. W., & Yantasee, W.
Venue
Nature Communications
Published
2022-07-23
Volume
13
Issue
1
Pages
4261-4261
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4286742004
Cited by
198
References
6
FWCI
15.50
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. https://app.cochat.ai/papers/10.1038/s41467-022-31926-9
The paper
Reda, M., Ngamcherdtrakul, W., Nelson, M. A., Siriwon, N., Wang, R., Zaidan, H. Y., Bejan, D. S., Reda, S., Hoang, N. H., Crumrine, N. A., Rehwaldt, J. P. C., Bindal, A., Mills, G. B., Gray, J. W., & Yantasee, W. (2022). Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nature Communications. https://doi.org/10.1038/s41467-022-31926-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.